Universität zu Köln

Jeck, Julia ORCID: 0000-0002-4669-690X, Jakobs, Florian, Kron, Anna ORCID: 0000-0002-3047-6486, Franz, Jennifer, Cornely, Oliver A. and Kron, Florian (2022). A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic first wave in a German tertiary care hospital. Infection, 50 (1). S. 191 - 202. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-0973

Full text not available from this repository.

Abstract

Purpose First detected in China in 2019, the novel coronavirus disease (COVID-19) has rapidly spread globally. Since then, healthcare systems are exposed to major challenges due to scarce personnel and financial resources. Therefore, this analysis intended to examine treatment costs of COVID-19 inpatients in a German single centre during the first pandemic wave in 2020 from a healthcare payer perspective. Potential cost savings were assessed considering the administration of remdesivir according to the European Medicines Agency label. Methods A retrospective medical-chart review was conducted on COVID-19 patients treated at University Hospital Cologne, Germany. Patients were clustered according to an eight-category ordinal scale reflecting different levels of supplemental oxygen. Potential cost savings due to the administration of remdesivir were retrospectively modelled based on a reduced length of stay, as shown in the Adaptive COVID-19 Treatment Trial. Results 105 COVID-19 patients were identified. There was wide variability in the service data with median treatment costs from EUR 900 to EUR 53,000 per patient, depending on major diagnosis categories and clinical severity. No supplemental oxygen was needed in 40 patients (38.1%). Forty-three (41.0%) patients were treated in intensive-care units, and 30 (69.8%) received invasive ventilation. In our model, in-label administration of remdesivir would have resulted in costs savings of EUR 2100 per COVID-19 inpatient (excluding acquisition costs). Conclusion We found that COVID-19 inpatients suffer from heterogeneous disease patterns with a variety of incurred G-DRG tariffs and treatment costs. Theoretically shown in the model, financial resources can be saved by the administration of remdesivir in eligible inpatients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Jeck, Julia UNSPECIFIED orcid.org/0000-0002-4669-690X UNSPECIFIED Jakobs, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kron, Anna UNSPECIFIED orcid.org/0000-0002-3047-6486 UNSPECIFIED Franz, Jennifer UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kron, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-575751
DOI:	10.1007/s15010-021-01685-8
Journal or Publication Title:	Infection
Volume:	50
Number:	1
Page Range:	S. 191 - 202
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1439-0973
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Infectious Diseases Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/57575